Passive immunization of chronic hepatitis B patients on lamivudine therapy: A feasible issue?

Journal of Viral Hepatitis

Volumn 9, Issue 3, 2002, Pages 221-228

  Van Nunen, A B ^a   De Man, R A ^a   Heijtink, R A ^a   Vossen, A C T M ^a   Schalm, S W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Anti HBs; Chronic hepatitis B; Lamivudine; Passive immunization

Indexed keywords

HEPATITIS B ANTIBODY; LAMIVUDINE; POLYCLONAL ANTIBODY; VIRUS DNA; VIRUS PROTEIN;

ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTITIS; DRUG EFFECT; DRUG EFFICACY; ECZEMA; FEMALE; HEPATITIS B; HUMAN; LIVER BIOPSY; MALE; PASSIVE IMMUNIZATION; PILOT STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; VIRION;

ADULT; COMBINED MODALITY THERAPY; DNA, VIRAL; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; LAMIVUDINE; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0036911182     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2002.00337.x     Document Type: Article

References (38)

1. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-323.
2. Krogsgaard K, Bindslev N, Christensen E et al. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. J Hepatol 1994; 21: 646-655.
3. Janssen HLA, Gerken G, Carreno V et al. Interferon a for chronic hepatitis B infection: Increased efficacy of prolonged treatment. Hepatology 1999; 30: 238-243.
4. Schalm SW, Heathcote J, Cianciara J et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. Gut 2000; 46: 562-568.
5. Lai CL, Chien RN, Leung NWY et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-68.
6. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 803-806.
7. Dienstag JL, Schiff ER, Mitchell M et al. Extended lamivudine retreatment for chronic hepatitis B. maintenance fo viral suppression after discontinuation of therapy. Hepatology 1999; 30: 1082-1087.
8. Liaw YF, Leung NW, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterol 2000; 119: 172-80.
9. Leung NWY, Lai CL, Chang TT et al. Three year lamivudine therapy in chronic HBV. J Hepatol 1999; 30: 59 (A).
10. Wolf HM, Eibl MM. Immunomodulatory effect of immunoglobulins. Clin Exp Rheumatol 1996; 14 (Suppl. 15): S17-S25.
11. Ip HMH, Lelie PN, Wong VCW, Kuhns MC, Reesink HW. Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. Lancet 1998, 406-10.
12. Beasley RP, Hwang LY, Lin CC et al. Hepatitis B immune globulin (HBIg) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Lancet 1981, 388-393.
13. Beasley RP, Hwang LY, Stevens CE et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state. Final report of a randomised double-blind, placebo-controlled trial. Hepatology 1983; 3: 135-141.
14. Canho R, Grosheide PM, Mazel JA et al. Ten-year neonatal hepatitis B vaccination program, the Netherlands, 1982-92: Protective efficacy and long-term immunogenicity. Vaccine 1997; 15: 1624-1630.
15. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847.
16. Man RA, Metselaar HJ, Heijtink RA, Schalm SW. Long-term application of human polyclonal hepatitis-B immunoglobulin to prevent hepatic allograft infection. Neth J Med 1993; 43: 74-82.
17. Muller R, Gubernatis G, Farle M et al. Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization. J Hepatol 1991; 13: 90-96.
18. Konig V, Hopf U, Neuhaus P et al. Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplantation 1994; 58: 553-559.
19. Reed WD, Eddleston ALWF, Cullens H et al. Infusion of hepatitis-B antibody in antigen-positive active chronic hepatitis. Lancet 1973, 1347-1351.
20. Eren R, Ilan E, Nussbaum O et al. Preclinical evaluation of two human anti-hepatitis B virus (HBV) monoclonal antibodies in the HBV-trimera mouse model and in HBV chronic carrier chimpanzees. Hepatology 2000; 32: 588-596.
21. Galun E, Eren R, Matot E, Shouval D, Terrault N, Keeffe E. Clinical evaluation (phase I) of a combination of two monoclonal antibodies to HBV, safety and antiviral properties. Hepatology 2000; 32: 240 (A).
22. Lever AML, Waters J, Brook MG, Karayiannis P, Thomas HC. Monoclonal antibody to HBsAg for chronic hepatitis B virus infection with hypogammaglobulinaemia. Lancet 1990; 335: 1529.
23. Wen YM, Wu XH, Hu DC, Zhang QP, Guo SQ. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet 1995; 345: 1575-1576.
24. McCluskie MJ, Di Wen YMQ, Davis HL. Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes. Viral Immunol 1998; 11: 245-252.
25. Celis E, Abraham KG, Miller RW. Modulation of the immunological response to hepatitis B virus by antibodies. Hepatology 1987; 7: 563-568.
26. Wen YM, Xiong SD, Zhang W. Solid matrix-antibody-antigen complex can clear viraemia and antigenaemia in persistent duck hepatitis B virus infection. J General Virol 1994; 75: 335-339.
27. Wen YM, Qu D, Zhou SH. Antigen-antibody complex as therapeutic vaccine for viral hepatitis B. Int Rev Immunol 1999; 18: 251-258.
28. Schilling R, Ljaz S, Williams R, Naoumov NV. Internalisation of monoclonal and polyclonal hepatitis B immunoglobulins in human hepatoma cells and their effect on the assembly and secretion of HBsAg. Hepatology (Suppl) 1999; 30: 246 (A).
29. Krawczynski K, Fattom A, Culver D et al. Experimental immune treatment of hepatitis C virus (HCV) infection: Passive anti-HCV (HBIg) transfer in chronically infected chimpanzees. J Hepatol (Suppl) 2000; 2: 37 (A).
30. Schneiders AM, Schulz M, Leifeld L et al. E2 antibodies mediate antibody dependent cellular cytotoxicity in HCV. J Hepatol (Suppl) 2000; 2: 37 (A).
31. Ostrow DH, Edwards B, Kimes D et al. Quantitation of hepatitis B surface antibody by an automated microparticle enzyme immunoassay. J Virol Methods 1991; 32: 265-276.
32. Mimms L, Goetze A, Swanson S et al. Second generation assays for the detection of antibody to HBsAg using recombinant DNA-derived HBsAg. J Virol Methods 1989; 25: 211-231.
33. Heijtink RA, Kruining J, Weber YAM, de Man RA, Schalm SW. Anti-hepatitis B virus activity of a mixture of two monoclonal antibodies in an 'inhibition in solution' assay. Hepatology 1995; 22: 1078-1083.
34. Honkoop P, de Man RA, Niesters HGM et al. Quantitative hepatitis B virus DNA assessment by means of the limiting dilution polymerase chain reaction in chronic hepatitis B patients during a 24-week course of lamivudine. J Viral Hep 1998; 5: 307-312.
35. Nevens F, Main J, Honkoop P et al. Lamivudine therapy for chronic hepatitis B. a six-month randomized dose-ranging study. Gastroenterology 1997; 113: 1258-1263.
36. Janssen HLA, Kerkhof-Los CJ, Heijtink RA, Schalm SW. Measurement of HBsAg to monitor hepatitis B viral replication in patients on alpha-interferon therapy. Antiviral Res 1994; 23: 251-257.
37. Wawrzynczak EJ. Antibody Therapy, 1st Edn. Oxford: Bios. Scientific Publishers Ltd, 1995.
38. Lau GKK, Liang R, Lee CK et al. Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core- and anti-hepatitis B surface antibody-positive. J Infect Dis 1998; 178: 1585-1591.